Picture of Longduoduo logo

LDDD — Longduoduo Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapFalling Star

Momentum

Relative Strength (%)
1m+1.66%
3m+2.54%
6m-1.17%
1yr-51.87%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w Highn/a
50d MAn/a
200d MAn/a

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-81.07%
Return on Equity-61.29%
Operating Margin-34.74%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202730th Jun 2028
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2027 / 2028

Blurred out image of Longduoduo EPS forecast chart

Profile Summary

Longduoduo Co Ltd is a company principally engaged the provision of preventive care services. The Company provides solution for chronic disease problems through non-drug treatments and prevents cardiovascular and cerebrovascular diseases in advance. The Company offers health consultation and advice to customers and sells treatment services to customers, provided by Longduoduo to customers in local cooperative medical institutions. The Company's treatment projects mainly include ozone autologous blood transfusion (immunotherapy), Xingnao Tongluo therapy, double blood purification, platelet-rich plasma (PRP) injection therapy and others. The Company's products and services are mainly used for the prevention of myocardial infarction, cerebral infarction, hemiplegia, cardiovascular and cerebrovascular diseases. The Company mainly conduct its businesses in domestic market.

Directors

Last Annual
June 30th, 2026
Last Interim
June 30th, 2026
Incorporated
October 25th, 2021
Public Since
August 17th, 2022
No. of Shareholders
50
No. of Employees
51
Sector
Healthcare Providers & Services
Industry
Healthcare
Exchange
us flag iconPink Sheets on Nasdaq
Shares in Issue
30,015,036

LDDD Share Price Performance

Upcoming Events for LDDD

Q1 2027 Longduoduo Co Ltd Earnings Release

Q2 2027 Longduoduo Co Ltd Earnings Release

Similar to LDDD

Picture of 4Cable TV International logo

4Cable TV International

us flag iconPink Sheets on Nasdaq

Picture of Abattis Bioceuticals logo

Abattis Bioceuticals

us flag iconPink Sheets on Nasdaq

Picture of Accelera Innovations logo

Accelera Innovations

us flag iconPink Sheets on Nasdaq

Picture of Quantum Medical Transport logo

Quantum Medical Transport

us flag iconPink Sheets on Nasdaq

FAQ